Advertisement

Topics

BioSpecifics Technologies (BSTC) versus Its Competitors Critical Analysis

13:59 EST 31 Dec 2017 | Topix

BioSpecifics Technologies is one of 286 public companies in the "Bio Therapeutic Drugs" industry, but how does it weigh in compared to its rivals? We will compare BioSpecifics Technologies to related businesses based on the strength of its analyst recommendations, profitability, valuation, risk, institutional ownership, earnings and dividends. BioSpecifics Technologies has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.

Original Article: BioSpecifics Technologies (BSTC) versus Its Competitors Critical Analysis

NEXT ARTICLE

More From BioPortfolio on "BioSpecifics Technologies (BSTC) versus Its Competitors Critical Analysis"

Advertisement
Quick Search
Advertisement
Advertisement